Meet Our Scientists
Ru Shen, MS
"I obtained my MS degree at SUNY-Binghamton. Prior joining EBI, I worked at Wyeth Oncology and Neuroscience Departments for fifteen years. I apply my skill set in molecular biology, microbiology, cell biology, biochemistry, histology, and imaging to drug discovery programs. During my seven years at EBI, I worked on almost every project from assay development to pre-clinical candidate selection. I am excited to see several of them are in clinical development."
Dong Liu, PhD
"I joined EBI in March 2010 as one of the first chemists. Since then, I have successfully delivered multiple preclinical candidates (PCC) in PARP, BRAF, BTK, EZH2, ROR agonist programs. SHR1459 (BTK inhibitor) and SHR2554 (EZH2 inhibitor) have enter phase I clinical trials. I have increased my responsibilities over the years, currently, I am leading the chemistry efforts of multiple projects from target evaluation, lead identification, lead optimization to PCC profiling and selection.
Prior to joining EBI, I worked on novel macrolide antibiotics and HCV protease inhibitor programs in Enanta Pharmaceuticals for 5 years. I made contributions to the discovery of two approved HCV drugs – Paritaprevir and Glecaprevir (part of Abbvie’s blockbuster drug Mavyret).
I received my Ph.D. in organic chemistry from the University of Chicago and B.S. in chemistry from Nanjing University."
Matthew Miller, PhD
Senior Principal Investigator
"After training as a structural biologist at Northwestern University, I completed a post-doc at the NIH studying protein-RNA interactions. As an assistant research professor at Rutgers University I was introduced to structure based drug design. At Eternity I am using my training and experience to help our medicinal chemists design the next generation of treatments for cancer and auto-immune disease."